A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Axogen, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 308,686 shares of AXGN stock, worth $5.31 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
308,686
Previous 185,568 66.35%
Holding current value
$5.31 Million
Previous $1.34 Million 222.19%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$7.52 - $14.69 $925,847 - $1.81 Million
123,118 Added 66.35%
308,686 $4.33 Million
Q2 2024

Aug 09, 2024

SELL
$5.67 - $8.06 $36,475 - $51,849
-6,433 Reduced 3.35%
185,568 $1.34 Million
Q1 2024

May 09, 2024

BUY
$6.63 - $10.69 $260,028 - $419,261
39,220 Added 25.67%
192,001 $1.55 Million
Q4 2023

Feb 09, 2024

BUY
$3.61 - $7.76 $3,169 - $6,813
878 Added 0.58%
152,781 $1.04 Million
Q3 2023

Nov 13, 2023

BUY
$4.68 - $9.26 $6,233 - $12,334
1,332 Added 0.88%
151,903 $759,000
Q2 2023

Aug 10, 2023

BUY
$8.5 - $10.38 $409,071 - $499,547
48,126 Added 46.98%
150,571 $1.37 Million
Q1 2023

May 09, 2023

BUY
$7.53 - $10.95 $173,988 - $253,010
23,106 Added 29.12%
102,445 $968,000
Q4 2022

Feb 10, 2023

BUY
$9.44 - $13.09 $223,709 - $310,206
23,698 Added 42.59%
79,339 $791,000
Q3 2022

Nov 10, 2022

BUY
$8.14 - $12.25 $43,028 - $64,753
5,286 Added 10.5%
55,641 $663,000
Q2 2022

Aug 05, 2022

BUY
$6.99 - $10.0 $178,056 - $254,730
25,473 Added 102.38%
50,355 $412,000
Q1 2022

May 12, 2022

BUY
$7.26 - $10.7 $180,643 - $266,237
24,882 New
24,882 $198,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $727M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.